XBIO vs. NNVC, ACST, NRXP, UBX, MEIP, BFRG, BIOR, PIRS, HCWB, and SPRB
Should you be buying Xenetic Biosciences stock or one of its competitors? The main competitors of Xenetic Biosciences include NanoViricides (NNVC), Acasti Pharma (ACST), NRx Pharmaceuticals (NRXP), Unity Biotechnology (UBX), MEI Pharma (MEIP), Bullfrog AI (BFRG), Biora Therapeutics (BIOR), Pieris Pharmaceuticals (PIRS), HCW Biologics (HCWB), and Spruce Biosciences (SPRB). These companies are all part of the "pharmaceutical preparations" industry.
Xenetic Biosciences (NASDAQ:XBIO) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, media sentiment, institutional ownership, analyst recommendations, community ranking, dividends and risk.
In the previous week, Xenetic Biosciences had 1 more articles in the media than NanoViricides. MarketBeat recorded 3 mentions for Xenetic Biosciences and 2 mentions for NanoViricides. Xenetic Biosciences' average media sentiment score of 0.96 beat NanoViricides' score of 0.16 indicating that Xenetic Biosciences is being referred to more favorably in the media.
Xenetic Biosciences received 174 more outperform votes than NanoViricides when rated by MarketBeat users. Likewise, 68.24% of users gave Xenetic Biosciences an outperform vote while only 0.00% of users gave NanoViricides an outperform vote.
15.1% of Xenetic Biosciences shares are owned by institutional investors. Comparatively, 10.3% of NanoViricides shares are owned by institutional investors. 9.0% of Xenetic Biosciences shares are owned by company insiders. Comparatively, 4.6% of NanoViricides shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Xenetic Biosciences has a beta of 2.28, meaning that its share price is 128% more volatile than the S&P 500. Comparatively, NanoViricides has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.
NanoViricides has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -182.99%. Xenetic Biosciences' return on equity of -43.40% beat NanoViricides' return on equity.
Xenetic Biosciences has higher revenue and earnings than NanoViricides. NanoViricides is trading at a lower price-to-earnings ratio than Xenetic Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Xenetic Biosciences beats NanoViricides on 12 of the 14 factors compared between the two stocks.
Get Xenetic Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for XBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xenetic Biosciences Competitors List
Related Companies and Tools
Free XBIO Stock Alerts